 Neurocrine should soon release Phase II data on NBI-827104, and a positive read-out on a largely overlooked drug today could add 5 to 10 to NBIXs fair value. Between the expansion of the sales force and new marketing initiatives, Neurocrine is looking to reignite sales momentum in Ingrezza, a drug that I still believe has meaningful growth potential. 